论文部分内容阅读
目的:探讨沙美特罗替卡松治疗慢性阻塞性肺疾病稳定期的临床疗效,为今后临床治疗提供参考和借鉴。方法:本研究随机选取我院2010年1月~2013年2月期间处于稳定期的慢性阻塞性肺疾病患者66例,采用随机数字法将其分为对照组和观察组,对照组采用常规治疗,观察组在常规治疗的基础之上采用沙美特罗替卡松治疗。对比分析两组患者治疗前后肺功能的改善情况以及治疗后的住院次数。结果:两组患者治疗结束后,观察组患者的肺功能改善情况明显优于对照组(P<0.05),差异有统计学意义;观察组的住院次数(0.12±0.02)次也明显少于对照组的(0.32±0.07)次(t=2.7472,P=0.0078),差异无统计学意义。结论:沙美特罗替卡松能有效治疗稳定期的慢性阻塞性肺疾病患者,疗效显著且安全性高,值得在临床实践中广泛的应用和推广。
Objective: To investigate the clinical efficacy of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease (COPD) in stable phase and to provide references for clinical treatment in the future. Methods: Sixty-six patients with chronic obstructive pulmonary disease (COPD) in our hospital from January 2010 to February 2013 were randomly selected. The patients were divided into control group and observation group by random number method. The control group received routine treatment The observation group was treated with salmeterol and fluticasone on the basis of routine treatment. Comparison of two groups of patients before and after treatment to improve lung function and the number of hospitalizations after treatment. Results: The improvement of pulmonary function in the observation group was better than that in the control group (P <0.05) after treatment, the difference was statistically significant; the number of hospitalization (0.12 ± 0.02) in the observation group was also significantly less than that in the control group Group (0.32 ± 0.07) times (t = 2.7472, P = 0.0078), the difference was not statistically significant. Conclusion: Salmeterol ticoson can effectively treat patients with chronic obstructive pulmonary disease in stable phase, with significant curative effect and high safety. It is worth to be widely used and popularized in clinical practice.